» Articles » PMID: 16515769

Idiopathic Hypercalciuria

Overview
Publisher Current Science
Specialty Rheumatology
Date 2006 Mar 7
PMID 16515769
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Hypercalcuria is the most common metabolic disorder found in patients with nephrolithiasis. As the prevalence of kidney stones rises in industrialized nations, understanding the pathogenesis and treatment of hypercalciuria becomes increasingly important. Idiopathic hypercalciuria (IH), defined as an excess urine calcium excretion without an apparent underlying etiology, is the most frequent cause of hypercalciuria and will be the focus of this paper. Calcium homeostasis is tightly controlled and slight disturbances in transport at the level of the intestine, bone, and/or kidney can lead to excessive urine calcium excretion and promote stone formation. IH is a systemic disorder with dysregulation of calcium transport at a combination of these calcium regulatory sites. The goal of treatment is to prevent stone formation and relies on a combination of dietary and pharmaceutical interventions. Dietary management includes increasing fluid intake, salt restriction, animal protein restriction, and maintaining a normal calcium intake. Thiazide diuretics have proven effective in preventing calcium stone formation by reducing the urinary excretion of calcium. It is important to note that while decreasing urinary calcium excretion is important the clinician should focus primarily on reducing the supersaturation of calcium oxalate as this determines the true tendency for stone formation.

Citing Articles

Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria.

Aliberti L, Gagliardi I, Gamberini M, Ziggiotto A, Verrienti M, Carnevale A Br J Haematol. 2022; 198(5):903-911.

PMID: 35768889 PMC: 9542302. DOI: 10.1111/bjh.18345.


Mutations in Are Not a Common Cause of Pediatric Idiopathic Hypercalciuria in Canada.

Ulrich E, Harvey E, Morgan C, Pinsk M, Erickson R, Robinson L Can J Kidney Health Dis. 2022; 9:20543581221098782.

PMID: 35615069 PMC: 9125053. DOI: 10.1177/20543581221098782.


Medical evaluation and pharmacotherapeutical strategies in management of urolithiasis.

Ng D, Haleem M, Mamuchashvili A, Wang K, Pan J, Cheng Y Ther Adv Urol. 2021; 13:1756287221993300.

PMID: 33708261 PMC: 7907714. DOI: 10.1177/1756287221993300.


Association between single nucleotide polymorphism (rs4252424) in TRPV5 calcium channel gene and lead poisoning in Chinese workers.

Liu J, Zhang L, Feng L, Xu M, Gao Y, Zhou P Mol Genet Genomic Med. 2019; 7(3):e562.

PMID: 30666830 PMC: 6418352. DOI: 10.1002/mgg3.562.


Biochemical diagnosis in 3040 kidney stone formers in Argentina.

Spivacow F, Del Valle E, Negri A, Fradinger E, Abib A, Rey P Urolithiasis. 2015; 43(4):323-30.

PMID: 25958053 DOI: 10.1007/s00240-015-0778-0.


References
1.
Yao J, Kathpalia P, Bushinsky D, Favus M . Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats. J Clin Invest. 1998; 101(10):2223-32. PMC: 508810. DOI: 10.1172/JCI1164. View

2.
Krieger N, Stathopoulos V, Bushinsky D . Increased sensitivity to 1,25(OH)2D3 in bone from genetic hypercalciuric rats. Am J Physiol. 1996; 271(1 Pt 1):C130-5. DOI: 10.1152/ajpcell.1996.271.1.C130. View

3.
Motoyama H, Friedman P . Calcium-sensing receptor regulation of PTH-dependent calcium absorption by mouse cortical ascending limbs. Am J Physiol Renal Physiol. 2002; 283(3):F399-406. DOI: 10.1152/ajprenal.00346.2001. View

4.
Hoenderop J, Muller D, van der Kemp A, Hartog A, Suzuki M, Ishibashi K . Calcitriol controls the epithelial calcium channel in kidney. J Am Soc Nephrol. 2001; 12(7):1342-1349. DOI: 10.1681/ASN.V1271342. View

5.
Moe O, Bonny O . Genetic hypercalciuria. J Am Soc Nephrol. 2005; 16(3):729-45. DOI: 10.1681/ASN.2004100888. View